Wegovy weight loss before and after: separating the evidence from the hype

The biggest misconception: before-and-after images tell you what to expect

The most persistent myth around Wegovy weight loss is that a compelling before-and-after photograph predicts your own outcome. It doesn't. If you want to understand what Wegovy before and after results actually look like across a broad range of people, the picture is considerably more nuanced than the photographs circulating online (on Instagram, TikTok and health forums), which are almost always unrepresentative in at least one direction. They tend to show people who responded well, photographed at the most striking angle, over a longer period than is usually stated. Some images involve doses, durations or combination approaches that bear no resemblance to a standard treatment course.

That isn't a reason to dismiss semaglutide's real-world impact. It is a reason to look at clinical trial data instead. The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks. Those taking semaglutide 2.4mg lost an average of around 15% of body weight, compared with about 2.4% in the placebo group. That is a clinically meaningful result. But average means half the participants lost more and half lost less. A before-and-after image captures one person's experience; the trial captures thousands.

If you want a quick reality check, weigh yourself, calculate 15% of that figure, and note what that number represents in kilograms. That is the average outcome from the trial, not a guarantee, but an honest anchor. Most people find that figure considerably more useful than any photograph.

How Wegovy results actually unfold over time

Weight loss with Wegovy is not a switch that flips. The dosing schedule starts at 0.25mg and steps upward roughly every four weeks (through 0.5mg, 1mg and 1.7mg) before reaching the 2.4mg maintenance dose. Each escalation exists to help your body adjust and to reduce gastrointestinal side effects. The practical consequence is that the first month or two rarely show the most change. You can read more about what to expect in those early weeks on our guide to Wegovy weight loss after one month.

The largest drops in body weight typically appear once maintenance dose is reached and sustained. Studies show weight loss tends to plateau somewhere between 52 and 72 weeks, which is why NHS guidance references treatment periods of up to two years when Wegovy is used within specialist weight management services. Progress is rarely linear: weeks of slower change are common and do not indicate the medicine has stopped working.

Lifestyle factors shape the outcome considerably. Semaglutide reduces appetite and slows gastric emptying, which makes it easier to eat less, but the medicine works alongside a reduced-calorie diet and increased activity, not instead of them. Our overview of what to know before starting semaglutide covers what to expect practically in the early weeks.

Who the evidence applies to, and the eligibility picture

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance. The NHS England guidance on weight management injections sets out the access criteria in detail.

NICE recommends semaglutide for NHS use only within specialist weight management services and for a maximum of two years, criteria that reflect both the medicine's profile and NHS capacity. Many people who meet the licensed eligibility criteria do not currently qualify for NHS provision, or face long waits. Private treatment through a regulated pharmacy is the alternative for that group, subject to an independent prescriber confirming suitability. You can explore what a private route involves on the Wegovy treatment page, or see how Wegovy compares with other options on our weight loss treatments overview.

One point worth stating clearly: a good before-and-after image is not an eligibility criterion. Clinical assessment is.

What happens to results if treatment stops

A question that comes up almost as often as the before-and-after discussion is what happens afterwards. The evidence here is consistent: when semaglutide is stopped, a significant portion of the weight lost tends to return over the following months, because the physiological effects of the medicine (reduced appetite, slower gastric emptying) reverse when dosing ends. This is not a sign that the treatment failed. It reflects the underlying biology of obesity as a chronic condition.

The decision about when and whether to stop is a clinical one, made with a prescriber who can weigh your progress, your health picture and your goals. Our guide to stopping Wegovy after weight loss covers this in more detail, including what the evidence says about weight regain timelines. For anyone considering the cost implications of longer-term treatment, our Wegovy cost context page explains what private treatment typically involves financially. A prescriber, not a photograph, is the right starting point for any of these decisions. If you'd like to speak to one of our clinical team, you can start a free consultation at any time.